Provista 002 prospective randomized trial utilizing Combinatorial Protein Biomarker Assay in comparison to Standard of Care Imaging: Detection of Breast Cancer in patients of 25-75 years assessed with BI-RADS 3 or 4.

Provista Diagnostics presented this poster at ASCO Breast 2015 demonstrating a non-invasive, blood-based combinatorial proteomic biomarker assay (Videssa® Breast) that is to be used as an adjunct to standard-of-care imaging to detect the presence or absence of breast cancer in patients of 25 - 75 years with BI-RADS3 or 4.

Learn more by downloading the scientific poster

HUPO-2016densebreast.png

Download Poster